NIH, Partners To Launch Phase 3 Trial To Evaluate HIV Vaccine Efficacy In MSM, Transgender People
National Institutes of Health: NIH and partners to launch HIV vaccine efficacy trial in the Americas and Europe
“The National Institutes of Health and partners [Monday] announced plans to conduct a Phase 3 HIV vaccine efficacy trial at multiple clinical research sites in North America, South America, and Europe. The trial, called HPX3002/HVTN 706 or Mosaico, will assess whether an investigational vaccine regimen designed to induce immune responses against a variety of global HIV strains can safely and effectively prevent HIV acquisition among men who have sex with men and transgender people…” (7/15).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.